Clinical News

<div class="articleContainer"><div class="articleWrapper"><div class="articleContent"><h1 class="text title">ImmunoGen down on Phase III ovarian cancer miss</h1><div class="byline">Brian Moy</div><div class="date"></div></div></div></div>

ImmunoGen Inc.

Ovarian cancer

mirvetuximab soravtansine (IMGN853)

Folate receptor 1 (FOLR1) (FR-alpha) (FOLR)

ImmunoGen down on Phase III ovarian cancer miss

Featured Analysis

Articles

Current Editions

Data Graphics

Podcasts & Webcasts

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data

All Events

China Healthcare Summit

Bio€quity Europe

Events

My Workspace

Company Overview

Management

Editorial & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Trial

Subscribe

Advertising & Sponsorship

Career Opportunities

Customer Resource Center

Contact

Home

<br/><center><span style="font-size:1.75rem;font-weight:500;">Access This Article</span></center>

Paywall Not Entitled Title

Request a Trial

Purchase This Article

<center><span style="font-weight:300;">[Subscribers Log in]{{login}}</span></center>

Paywall Sub log in